The increased neopterin content in turkish pediatric patients with sickle cell anemia

[1]  S. El Aidy,et al.  University of Groningen Role of Microbiota and Tryptophan Metabolites in the Remote Effect of Intestinal Inflammation on Brain and Depression , 2018 .

[2]  P. Szcześniak,et al.  Neopterin as a marker of cellular immunological response. , 2017, Postepy higieny i medycyny doswiadczalnej.

[3]  M. Ughasoro,et al.  Anaemia of Chronic Disease: An In-Depth Review , 2016, Medical Principles and Practice.

[4]  Zeliha Kayaalti,et al.  Türkiye’de orak hücreli anemi dağılımı, patofizyolojisi ve demir toksisitesi , 2016 .

[5]  M. Heistermann,et al.  Urinary neopterin, a non-invasive marker of mammalian cellular immune activation, is highly stable under field conditions , 2015, Scientific Reports.

[6]  Andrew C. Terentis,et al.  Role of indoleamine 2,3-dioxygenase in health and disease. , 2015, Clinical science.

[7]  M. Zou,et al.  Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation. , 2015, Frontiers in bioscience.

[8]  F. V. Pericole,et al.  Cytokines Polymorphisms and Relationship with Cytokine Expression in Sickle Cell Disease , 2014 .

[9]  George M Whitesides,et al.  Density-based separation in multiphase systems provides a simple method to identify sickle cell disease , 2014, Proceedings of the National Academy of Sciences.

[10]  E. Roze,et al.  Simultaneous determination of all forms of biopterin and neopterin in cerebrospinal fluid. , 2014, ACS chemical neuroscience.

[11]  R. Kruse-Jarres,et al.  Management of sickle cell disease from childhood through adulthood. , 2013, Blood reviews.

[12]  G. Solgi,et al.  Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition. , 2013, European cytokine network.

[13]  B. Pace,et al.  Sickle Cell Disease: Genetics, Cellular and Molecular Mechanisms, and Therapies , 2012, Anemia.

[14]  D. Fuchs,et al.  Tryptophan degradation and serum neopterin concentrations in intensive care unit patients , 2011, Toxicology mechanisms and methods.

[15]  G. Kato,et al.  The proteome of sickle cell disease: insights from exploratory proteomic profiling , 2010, Expert review of proteomics.

[16]  K. Channon,et al.  Tetrahydrobiopterin: pleiotropic roles in cardiovascular pathophysiology , 2010, Heart.

[17]  A. Mamman,et al.  Pattern of Serum Cytokine Expression and T-Cell Subsets in Sickle Cell Disease Patients in Vaso-Occlusive Crisis , 2010, Clinical and Vaccine Immunology.

[18]  E. Vichinsky,et al.  Severe sickle cell disease--pathophysiology and therapy. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  T. Baydar,et al.  Neopterin as a prognostic biomarker in intensive care unit patients. , 2009, Journal of critical care.

[20]  S. Saad,et al.  Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy , 2009, Journal of leukocyte biology.

[21]  G. Guillemin,et al.  Kynurenine Pathway Metabolites in Humans: Disease and Healthy States , 2009, International journal of tryptophan research : IJTR.

[22]  D. Fuchs,et al.  Accelerated Tryptophan Degradation in Trauma and Sepsis Patients is Related to Pro-inflammatory Response and to the Diminished in vitro Response of Monocytes , 2009 .

[23]  E. Fibach,et al.  The role of oxidative stress in hemolytic anemia. , 2008, Current molecular medicine.

[24]  Winfred C. Wang.  The pathophysiology, prevention, and treatment of stroke in sickle cell disease , 2007, Current opinion in hematology.

[25]  F. Costa,et al.  High levels of neopterin and interleukin‐3 in sickle cell disease patients , 2006, Journal of clinical laboratory analysis.

[26]  A. Duits,et al.  Sickle cell disease; a general overview. , 2004, The Netherlands journal of medicine.

[27]  R. Osarogiagbon,et al.  The Endothelial Biology of Sickle Cell Disease: Inflammation and a Chronic Vasculopathy , 2004, Microcirculation.

[28]  E. Vichinsky,et al.  Managing sickle cell disease , 2003, BMJ : British Medical Journal.

[29]  N. Nardi,et al.  Sickle cell disease: a chronic inflammatory condition. , 2001, Medical hypotheses.

[30]  E. Hatzimichael,et al.  The role of cytokines in sickle cell disease , 2000, Annals of Hematology.

[31]  N. Blau,et al.  Tetrahydrobiopterin biosynthesis, regeneration and functions. , 2000, The Biochemical journal.

[32]  G. Weiss,et al.  Iron and anemia of chronic disease. , 1999, Kidney international. Supplement.

[33]  E. Werner,et al.  Simultaneous measurement of serum tryptophan and kynurenine by HPLC. , 1997, Clinical chemistry.

[34]  Rm,et al.  Sickle cell disease , 1996 .

[35]  D. Fuchs,et al.  The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. , 1992, Critical reviews in clinical laboratory sciences.

[36]  S. Taylor,et al.  Interferon production in sickle cell disease. , 1990, Lymphokine research.

[37]  E. Werner,et al.  Parallel induction of tetrahydrobiopterin biosynthesis and indoleamine 2,3-dioxygenase activity in human cells and cell lines by interferon-gamma. , 1989, The Biochemical journal.

[38]  S. Milstien,et al.  Tetrahydrobiopterin, the cofactor for aromatic amino acid hydroxylases, is synthesized by and regulates proliferation of erythroid cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Winfred C. Wang,et al.  Lymphocyte and complement abnormalities in splenectomized patients with hematologic disorders , 1988, American journal of hematology.

[40]  A. Sasco,et al.  Cell-mediated immunity in patients with sickle cell anaemia. , 1988, Thymus.